We are live on ! Find out more
NHAS

Novo Holdings A/S Portfolio holdings

AUM $1.23B
1-Year Est. Return 81.32%
This Fund
S&P 500
This Quarter Est. Return
+26.7%
1 Year Est. Return
+81.32%
3 Year Est. Return
+192.63%
5 Year Est. Return
+125.03%
10 Year Est. Return
+943.65%
AUM
$1.55B
AUM Growth
+$135M
Cap. Flow
-$139M
Cap. Flow %
-8.96%
Top 10 Hldgs %
73.16%
Holding
30
New
1
Increased
5
Reduced
9
Closed
3

Top Buys

Rank Stock Value
1
BBOT
BridgeBio Oncology
BBOT
+$20.4M
2
ELVN icon
Enliven Therapeutics
ELVN
+$6.89M
3
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$2.4M
4
APGE icon
Apogee Therapeutics
APGE
+$1.93M
5
AVBP icon
ArriVent BioPharma
AVBP
+$1.38M

Top Sells

Rank Stock Value
1
INSM icon
Insmed
INSM
+$58.8M
2
BPMC
Blueprint Medicines
BPMC
+$34M
3
CBLL
CeriBell Inc
CBLL
+$16.9M
4
ASML icon
ASML
ASML
+$15.7M
5
BABA icon
Alibaba
BABA
+$15.1M

Sector Composition

Rank Sector Weight
1 Healthcare 50.22%
2 Technology 14.29%
3 Financials 10.3%
4 Consumer Discretionary 2.96%
5 Industrials 0.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IOBT
26
DELISTED
IO Biotech
IOBT
$912K 0.06%
2,512,453
-841,996
-25% -$1.45M
DMRA
27
Damora Therapeutics, Inc. Ordinary Shares
DMRA
$1.84B
$322K 0.02%
86,579
-13,334
-13% -$45.2K
ABCL icon
28
AbCellera Biologics
ABCL
$2.12B
– –
-652,529
Closed -$2.24M
BPMC
29
DELISTED
Blueprint Medicines
BPMC
– –
-264,956
Closed -$34M
CBLL
30
CeriBell Inc
CBLL
$714M
– –
-900,000
Closed -$16.9M
1
2

Similar funds

MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
HTHT
Hemenway Trust Hemenway Trust Salem, New Hampshire $1.24B AUM 16.52% 1-Year Est. Return
BCP
BlackBarn Capital Partners New York $1.24B AUM 55.98% 1-Year Est. Return
SPC
Stony Point Capital New York $1.24B AUM 32.69% 1-Year Est. Return
SC
Strategy Capital Los Altos, California $1.22B AUM 27.02% 1-Year Est. Return

Novo Holdings A/S's Q3 2025 Portfolio in Review

As of Q3 2025, Novo Holdings A/S held 30 positions worth $1.55B, up 9.5% from $1.42B the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Novo Holdings A/S withdrew a net $139M in Q3 2025, closing 3 positions and reducing 9 holdings. Its most notable exit was Blueprint Medicines, an estimated $34M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 50% of assets, up from 48% a quarter earlier, followed by Technology and Financials.

Against the trend, Novo Holdings A/S opened a new position in BridgeBio Oncology worth $22.7M.

  • Novo Holdings A/S's largest Q3 2025 buy was BridgeBio Oncology: 1,961,317 shares worth $22.7M.
  • Novo Holdings A/S added most to Enliven Therapeutics in Q3 2025, an estimated $6.89M increase.
  • Novo Holdings A/S's biggest Q3 2025 reduction was Insmed, cutting an estimated $58.8M.
  • Novo Holdings A/S fully exited Blueprint Medicines in Q3 2025, selling an estimated $34M.
  • Novo Holdings A/S's ten largest holdings make up 73% of its $1.55B portfolio in Q3 2025.
  • Novo Holdings A/S opened 1 new position and closed 3 in Q3 2025.
  • Novo Holdings A/S's portfolio value rose 9.5% quarter-over-quarter to $1.55B.

Based on Novo Holdings A/S's 13F filing for Q3 2025, filed 14 Nov 2025.